[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acrivon Therapeutics Inc (ACRV)

Acrivon Therapeutics Inc (ACRV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,047
  • Shares Outstanding, K 42,802
  • Annual Sales, $ 0 K
  • Annual Income, $ -77,910 K
  • EBIT $ -82 M
  • EBITDA $ -81 M
  • 60-Month Beta 1.85
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.49
  • Number of Estimates 3
  • High Estimate $-0.47
  • Low Estimate $-0.50
  • Prior Year $-0.55
  • Growth Rate Est. (year over year) +10.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4100 +21.99%
on 07/30/26
2.1550 -20.19%
on 07/14/26
-0.2400 (-12.24%)
since 07/10/26
3-Month
1.3600 +26.47%
on 06/11/26
2.1550 -20.19%
on 07/14/26
-0.1700 (-8.99%)
since 05/12/26
52-Week
1.2500 +37.60%
on 08/13/25
3.5600 -51.69%
on 01/07/26
+0.4700 (+37.60%)
since 08/12/25

Most Recent Stories

More News
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 ACR-2316 Phase 1/2 trial in AP3-prioritized tumor...

ACRV : 1.7200 (-0.58%)
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly regimen...

ACRV : 1.7200 (-0.58%)
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

Presentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1 inhibitor, rationally designed with AP3 for potent single agent activity and superior therapeutic index...

ACRV : 1.7200 (-0.58%)
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing...

ACRV : 1.7200 (-0.58%)
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing...

ACRV : 1.7200 (-0.58%)
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts

The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms in...

ACRV : 1.7200 (-0.58%)
A Breakout Year for WEE1? Oppenheimer Sees 6x Upside in This Under-the-Radar Biotech

Analysts have initiated bullish coverage of Aprea Therapeutics with price targets up to 6x current levels, citing the superior safety profile and $700M peak sales potential of its WEE1 inhibitor program...

AZN : 158.50 (-0.16%)
ZNTL : 4.29 (+4.38%)
ACRV : 1.7200 (-0.58%)
SDGR : 18.63 (-0.11%)
APRE : 0.6830 (+3.47%)
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 (Topo 1) inhibition ...

ACRV : 1.7200 (-0.58%)
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing...

ACRV : 1.7200 (-0.58%)
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC) Late-breaking oral presentation...

ACRV : 1.7200 (-0.58%)

Business Summary

Acrivon Therapeutics Inc. is a clinical stage biopharmaceutical company developing precision oncology medicines which matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon's proprietary proteomics-based patient responder identification platform,...

See More

Key Turning Points

3rd Resistance Point 1.7967
2nd Resistance Point 1.7733
1st Resistance Point 1.7467
Last Price 1.7200
1st Support Level 1.6967
2nd Support Level 1.6733
3rd Support Level 1.6467

See More

52-Week High 3.5600
Fibonacci 61.8% 2.6776
Fibonacci 50% 2.4050
Fibonacci 38.2% 2.1324
Last Price 1.7200
52-Week Low 1.2500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.